慢溃宁方对DSS诱导溃疡性结肠炎小鼠NLRP3/Caspase-1/GSDMD细胞焦亡通路和肠道菌群的影响

目的 探讨慢溃宁方对葡聚糖硫酸钠（DSS）诱导的溃疡性结肠炎（UC）小鼠肠道菌群的调控作用,和对NOD样受体（NLR）P3/胱天蛋白酶（Caspase）-1/Gasdermin D（GSDMD）细胞焦亡通路所介导炎症的影响。方法 SPF级C57BL/6小鼠60只,随机分为空白组、模型组、慢溃宁方组（20 g·kg^-1）、美沙拉秦组（0.266 g·kg^-1）,各组15只。小鼠通过自由饮用3%DSS溶液,7 d构建UC模型。造模开始12 h后,治疗组每天灌胃给药,其余组灌胃等体积生理盐水。记录小鼠每日体质量等情况,并评估计算疾病活动指数（DAI）。第8天麻醉后,脱臼颈椎处死小鼠,收集结肠和粪便,记量结肠长度;观察结肠组织苏木素-伊红（HE）染色后的病理学改变;结肠中肿瘤坏死因子-α（TNF-α）、白细胞介素-1β（IL-1β）、白细胞介素-18（IL-18）水平用酶联免疫吸附测定法（ELISA）检测;基于16S rRNA测序技术检测各组小鼠粪便中肠道菌群的差异;NLRP3/Caspase-1/GSDMD蛋白结肠组织中含量用蛋白免疫印迹法（Western blot）检测。结果 相较于空白组,模型组小鼠的DAI升高（P<0.01）,结肠长度显著缩短（P<0.01）,结肠黏膜损伤严重,TNFα、IL-1β、IL-18水平均明显升高（P<0.01）,且结肠组织中NLRP3/Caspase-1/GSDMD蛋白含量显著升高（P<0.01）,肠道菌群结构改变,门水平上的放线菌门、拟杆菌门与变形菌门丰度减少,厚壁菌门丰度增加;属水平上的乳酸杆菌、普雷沃氏菌和鼠杆菌属丰度减少,拟杆菌属、芽孢杆菌、毛螺旋菌属NK4A136丰度增加。慢溃宁方组、美沙拉秦组相较于模型组,第3天后DAI显著降低（P<0.01）,结肠长度均显著增加（P<0.01）,结肠的炎症浸润及黏膜结构损伤减轻,且结肠TNF-α、IL-1β、IL-18水平均显著下降（P<0.01）,NLRP3/Caspase-1/GSDMD蛋白在结肠组织中的含量明显降低（P<0.05,P<0.01）,门水平上的变形菌门和拟杆菌门丰度增加,厚壁菌门丰度减少。结论 慢溃宁方可通过抑制细胞经典焦亡通路,缓解UC小鼠结肠炎症反应,减轻结肠损伤,并对肠道菌群紊乱有改善作用。     

Amino Acid Formula Containing Synbiotics in Infants with Cow’s Milk Protein Allergy: A Systematic Review and Meta-Analysis

Cow’s milk protein allergy (CMPA) is associated with dysbiosis of the infant gut microbiome, with allergic and immune development implications. Studies show benefits of combining synbiotics with hypoallergenic formulae, although evidence has never been systematically examined. This review identified seven publications of four randomised controlled trials comparing an amino acid formula (AAF) with an AAF containing synbiotics (AAF-Syn) in infants with CMPA (mean age 8.6 months; 68% male, mean intervention 27.3 weeks, n = 410). AAF and AAF-Syn were equally effective in managing allergic symptoms and promoting normal growth. Compared to AAF, significantly fewer infants fed AAF-Syn had infections (OR 0.35 (95% CI 0.19–0.67), p = 0.001). Overall medication use, including antibacterials and antifectives, was lower among infants fed AAF-Syn. Significantly fewer infants had hospital admissions with AAF-Syn compared to AAF (8.8% vs. 20.2%, p = 0.036; 56% reduction), leading to potential cost savings per infant of £164.05–£338.77. AAF-Syn was associated with increased bifidobacteria (difference in means 31.75, 95% CI 26.04–37.45, p < 0.0001); reduced Eubacterium rectale and Clostridium coccoides (difference in means −19.06, 95% CI −23.15 to −14.97, p < 0.0001); and reduced microbial diversity (p < 0.05), similar to that described in healthy breastfed infants, and may be associated with the improved clinical outcomes described. This review provides evidence that suggests combining synbiotics with AAF produces clinical benefits with potential economic implications.     

Long-Term Safety and Efficacy of Prebiotic Enriched Infant Formula—A Randomized Controlled Trial

The present study aims to evaluate the effects of an infant formula supplemented with a mixture of prebiotic short and long chain inulin-type oligosaccharides on health outcomes, safety and tolerance, as well as on fecal microbiota composition during the first year of life. In a prospective, multicenter, randomized, double-blind study, n = 160 healthy term infants under 4 months of age were randomized to receive either an infant formula enriched with 0.8 g/dL of Orafti^®Synergy1 or an unsupplemented control formula until the age of 12 months. Growth, fever (>38 °C) and infections were regularly followed up by a pediatrician. Digestive symptoms, stool consistency as well as crying and sleeping patterns were recorded during one week each study month. Fecal microbiota and immunological biomarkers were determined from a subgroup of infants after 2, 6 and 12 months of life. The intention to treat (ITT) population consisted of n = 149 infants. Both formulae were well tolerated. Mean duration of infections was significantly lower in the prebiotic fed infants (p < 0.05). The prebiotic group showed higher Bifidobacterium counts at month 6 (p = 0.006), and higher proportions of Bifidobacterium in relation to total bacteria at month 2 and 6 (p = 0.042 and p = 0.013, respectively). Stools of infants receiving the prebiotic formula were softer (p < 0.05). Orafti^®Synergy1 tended to beneficially impact total daily amount of crying (p = 0.0594). Supplementation with inulin-type prebiotic oligosaccharides during the first year of life beneficially modulates the infant gut microbiota towards higher Bifidobacterium levels at the first 6 months of life, and is associated with reduced duration of infections.     

益元止泻颗粒对脾虚泄泻小鼠肠道菌群的影响

目的 探讨以四君子汤加味研制而成的益元止泻颗粒治疗脾虚泄泻的作用机制。方法 观察益元止泻颗粒对大黄煎剂所致脾虚泄泻小鼠肠道菌群的影响。结果 益元止泻颗粒对实验性脾虚泄泻小鼠的肠道菌群有调节作用,能增加有益菌如双歧杆菌、乳酸杆菌的数量。结论 益元止泻颗粒能调节肠道微生态平衡,从而对脾虚泄泻的恢复有重要影响。     

心痛安颗粒剂对不稳定性心绞痛患者血小板功能及凝血系统的影响

目的 :观察心痛安颗粒剂对不稳定性心绞痛患者血小板和凝血系统的作用。方法 :6 0例不稳定性心绞痛患者随机分为心痛安组 (30例 ,常规西药加心痛安颗粒剂治疗 )与对照组 (30例 ,单用常规西药治疗 ) ,观察治疗前后血小板最大聚集率 (Ma% )血小板 α颗粒膜糖蛋白 (GMP- 140 )和 D-二聚体 (D- D)的变化。结果 :治疗后 ,心痛安颗粒组的 Ma% ,GMP- 140和 D- D经治疗后明显下降 ,下降幅度明显大于对照组。结论 :心痛安颗粒剂可能通过抑制血小板聚集、活化和纤维蛋白合成而发挥治疗不稳定性心绞痛的作用。     

Safety and efficacy of traditional Chinese medicine,Qiaoshao formula,combined with dapoxetine in the treatment of premature ejaculation: An open-label,real-life,retrospective multicentre study in Chinese men

To evaluate the safety and efficacy of Chinese medicine, Qiaoshao formula combined with dapoxetine was used for the treatment of premature ejaculation in a real-life setting. Nine hundred and five males diagnosed with premature ejaculation were reviewed in this retrospective cohort study. We divided the patients into two groups: dapoxetine alone and Qiaoshao formula combined with dapoxetine according to actual interventions provided to patients in clinics. The perceived intravaginal ejaculation latency time and the premature ejaculation profile measures markedly improved in both groups. However, in men with severe premature ejaculation (baseline perceived intravaginal ejaculation latency time <1 min) and those with baseline age ≤30 years, the perceived intravaginal ejaculation latency time was slightly but significantly longer with combined therapy than with dapoxetine alone (p < .05). Therefore, combined therapy involving the Qiaoshao formula and dapoxetine proved to safe as well as effective for treating premature ejaculation while prolonging the perceived intravaginal ejaculation latency time, which significantly improved the overall satisfaction of the patient and likely that of the couple.     

Is the Parkland formula still the best method for determining the fluid resuscitation volume in adults for the first 24 hours after injury? — A retrospective analysis of burn patients in Germany

BackgroundR Rapid fluid resuscitation is a crucial therapy during the treatment of patients with extensive burns. In 1968, the Parkland Formula was introduced for the calculation of the estimated volume of the resuscitation fluid. Since then, different methods for the calculation of fluid resuscitation volume have been developed. We aimed to evaluate if the Parkland formula is still the most effective method for fluid resuscitation volume calculation in burn patients.MethodsIn the period between January 2015 and January 2019, data from 569 patients over 16 years old with burns of more than 20% total body surface area (TBSA) and at least 15% TBSA full thickness burns were entered in the German burn registry. The patients were divided into 5 groups (0, +1, ?1, +2, ?2) according to the volume of the resuscitation fluid they received. Group 0 patients received the amount of fluid calculated according to the Parkland formula (n = 83). The 4 other groups received reduced (-1, -2) or increased (+1, +2) fluid volumes in comparison to the value obtained by the Parkland formula.ResultsPatients in Group 0 presented a significantly lower mortality in the first week (4.5%) compared to groups –2 (16.7%) and group +2 (19.5%) (p = 0.021). Furthermore, the mean number of operations in group +2 (5.81) was higher than in group ?2 (3.81). Surviving patients from group +2 presented a longer hospital stay (68.1 days) compared to the other groups. Additionally, the logistic regression analysis showed a higher survival of patients in groups ?2 and ?1 (regression coefficients ?0.11 and ?0.086; Odds Ratio 0.896 and 0.918; 95% Confidence Interval (CI) 0,411–1.951 and 0.42–2.004).ConclusionIn this retrospective study, register based analysis a restrictive fluid regime was associated with a higher survival compared to the liberal Parkland guided fluid regime.     

膜肾1号方对大鼠肾脏病理及PI3K/Akt/mTOR信号通路表达的影响

[目的] 观察膜肾1号方对膜性肾病大鼠肾脏病理的改善作用及其对自噬通路磷脂肌醇3-激酶（PI3K）/蛋白激酶B（AKT）/雷帕霉素靶蛋白（mTOR）相关蛋白表达的影响。[方法] 将大鼠随机分为对照组、模型组、膜肾1号方高剂量组、中剂量组、低剂量组,盐酸贝那普利组。采用大鼠尾静脉注射阳离子化牛血清白蛋白（C-BSA）的方法建立MN大鼠模型,灌胃、取材。苏木精-伊红（HE ）染色法观察大鼠肾脏组织病理改变;免疫球蛋白G（IgG）免疫荧光染色观察大鼠IgG沉积;蛋白免疫印迹法（Western Blot）检测PI3K/Akt/mTOR 信号通路相关蛋白及自噬相关蛋白轻链3（LC3）表达。[结果] 药物干预后,膜肾1号方组大鼠24 h尿蛋白、三酰甘油、总胆固醇、低密度脂蛋白下降且低于模型组,并具有统计学差异（P＜0.05）。光镜下观察,HE染色示正常组肾组织整体结构基本正常,膜性肾病（MN）模型组肾小球毛细血管丛充血,系膜增生,基底膜出现增厚,部分肾小管细胞空泡变、组织内可见炎症细胞浸润,可见嗜复红蛋白及IgG沉积。经膜肾1号方和盐酸贝那普利干预后,大鼠肾脏病理学改变均有所减轻。各组大鼠IgG沉积显示,与对照组比较模型组IgG沉积明显,IgG荧光表达升高,差异具有统计学意义（P＜0.05）,盐酸贝那普利组和膜肾1号方组IgG荧光表达下降且低于模型组,具有统计学差异（P＜0.05）。Western Blot检测显示,药物干预后,盐酸贝那普利组和膜肾1号方组大鼠PI3K-Akt信号通路相关蛋白表达下降,LC3 表达增加,并具有统计学差异（P＜0.05）。[结论] 膜肾1号方可改善大鼠肾脏病理损伤,膜肾1号方干预后PI3K-Akt信号通路相关蛋白磷酸化磷酸肌醇3激酶（p-PI3K）,磷酸化Akt蛋白（p-Akt）,磷酸化雷帕霉素靶蛋白（p-mTOR）表达明显降低,自噬相关蛋白LC3表达升高,其分子机制与自噬信号通路的调控有关。     

水提干法制粒的中药配方颗粒溶化性与粉体物理属性相关性研究

目的 为加快实现中药生产过程中对中药配方颗粒的质量控制,从粉体物料属性出发,探究其对水提工艺下干法制粒的中药配方颗粒溶化性影响机制。方法 以60种中药配方颗粒及中间体混合粉为研究对象,通过对各品种混合粉粉体属性进行测定,建立粉体物性参数与颗粒溶化性关联模型。采用二维矩阵热点图对各品种间及物性指标间相似性进行分析,结合系统聚类分析对其进行归类,并运用多元统计方法初步筛选影响水提工艺下中药配方颗粒溶化性的关键因素。结果 各品种间粉体物性参数相关系数在-0.951～1.000,并按照各品种物理属性大致可以分为5类,结合变量投影响应值（variable importance for the projection,VIP）、自变量回归系数与方差膨胀因子（variance inflation factor,VIF）分析,最终筛选出其休止角（α）、含水量（HR）、吸湿性（H）与比表面积（SSA）4个指标为影响中药配方颗粒溶化性的关键物料属性（critical material attributes,CMAs）。结论 基于中药粉体物料属性与数据分析初步探寻影响水提条件下干法制粒的中药配方颗粒的溶化性机...     

基于“病-药-量”探讨《中华医典》含竹沥中药方剂相应规律的数据挖掘

目的 分析《中华医典》中含有竹沥中药方剂“病-药-量”的相应规律,为竹沥的临床诊疗应用及深入研发提供参考。方法 收集整理《中华医典》中含有竹沥的中药方剂,录入Excel 2016构建临证方药数据库,对其病症、证型、药物使用频次、功效类别、性味归经、剂型及用量等进行统计分析,运用SPSS Statistics 22.0、IBM SPSS Modeler 18.0软件进行关联规则、聚类分析等数据挖掘。结果 共收集含竹沥方剂349首,主治病证分类共99种,其中高频病证（≥20次）主要为“中风”“痰饮”“咳嗽”,治疗“中风”证型以风痰瘀阻为主,“痰饮”以饮停胃肠为主,“咳嗽”以痰热郁肺为主;组方中使用频次≥50次的药物有19味,使用频次较高的有生姜、甘草、茯苓、陈皮等,药物功效种类以化痰止咳平喘药、补虚药、清热药为主;药性使用频次最高的为寒性药,其次为温性药,药味多选用甘、苦、辛味,药物归经以脾、胃、心经为主;高频病症剂型及药物用量分析显示,治疗“中风”时,剂型多为汤剂,竹沥用量多为100 mL,核心药物配伍重用防风以祛风化痰,改善脑络痹阻;治疗“痰饮”时,剂型多为丸剂,竹沥用量为200 mL...